Novel 2‐Alkoxy‐3‐Cyanopyridine Derivatives as Cholinesterase Inhibitors: Synthesis, Biological Evaluation, and In Silico Investigations
Chemistry & Biodiversity · 2025
DOI: 10.1002/cbdv.202402915 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2025. Verfasst von Ibtissem Kadi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Synthesis of Molecules with Biological Interest, University of Frères Mentouri Constantine 1, Constantine, Algeria. Hauptthemen laut MEDLINE: Acetylcholinesterase, Butyrylcholinesterase, Cholinesterase Inhibitors, Pyridines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
Alzheimer's disease remains a major challenge in neuroscience and medicine. Cholinesterase inhibitors provide symptomatic relief but do not alter disease progression. While significant progress has been made in understanding its biology, there is an urgent need for effective therapies. In this study, a series of 2‐alkoxy‐3‐cyanopyridine derivatives ( 1 – 7 ) were prepared and evaluated as inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). Among the compounds, 3 and 4 were identified as good inhibitors of AChE and BuChE with relatively low IC 50 values. 3 inhibited AChE with an IC 50 of 53.95 ± 4.29 µM, while 4 had a greater potency for BuChE with an IC 50 of 31.79 ± 0.38 µM. Kinetic studies revealed that 3 and 4 are competitive inhibitors with K i values of 14.23 ± 0.42 and 19.80 ± 3.38 µM for AChE and BuChE, respectively. In silico investigations, including docking studies, DFT calculations, and ADME/drug‐likeness properties, were carried out to understand the mode of interaction of 3 and 4 toward the AChE and BuChE enzymes, as well as to determine their molecular geometry, chemical reactivity, and pharmacokinetic properties. This study highlights the potential of 3‐cyanopyridine derivatives in the treatment of AD and provides a solid foundation for further optimization and exploration of their therapeutic applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Synthesis of Molecules with Biological Interest, University of Frères Mentouri Constantine 1, Constantine, Algeria.
- Department of Biochemistry, Faculty of Pharmacy, Karadeniz Technical University, Trabzon, Türkiye.
- Department of Chemistry, Faculty of Exact Sciences, University of Frères Mentouri Constantine 1, Constantine, Algeria.
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Hacettepe University, Ankara, Türkiye.
- Experimental Medicine Application & Research Center, University of Health Sciences, Istanbul, Türkiye.
- Department of Biotechnology, University of Health Sciences, Istanbul, Türkiye.
ORCID-Profile: Houssem Boulebd
Zitieren
APA
Kadi, I., Seyhan, G., Zebbiche, Z., Sari, S., Barut, B., Boumoud, T., Mermer, A., & Boulebd, H. (2025). Novel 2‐Alkoxy‐3‐Cyanopyridine Derivatives as Cholinesterase Inhibitors: Synthesis, Biological Evaluation, and In Silico Investigations. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202402915
Vancouver
Kadi I, Seyhan G, Zebbiche Z, Sari S, Barut B, Boumoud T, et al. Novel 2‐Alkoxy‐3‐Cyanopyridine Derivatives as Cholinesterase Inhibitors: Synthesis, Biological Evaluation, and In Silico Investigations. Chemistry & Biodiversity. 2025. doi:10.1002/cbdv.202402915
BibTeX
@article{Kadi2025,
author = {Kadi, Ibtissem and Seyhan, Gökçe and Zebbiche, Zineddine and Sari, Suat and Barut, Burak and Boumoud, Taoues and Mermer, Arif and Boulebd, Houssem},
title = {Novel 2‐Alkoxy‐3‐Cyanopyridine Derivatives as Cholinesterase Inhibitors: Synthesis, Biological Evaluation, and In Silico Investigations},
journal = {Chemistry & Biodiversity},
year = {2025},
doi = {10.1002/cbdv.202402915}
}
EUVIMED